A delivery assembly includes a console including a vial containment region and a vial engagement mechanism extending from the console within the vial containment region. The engagement mechanism is configured to engage a vial assembly. The delivery assembly further includes a sled assembly removably coupled to the console at the vial containment region and a safety shield removably coupled to the console over the vial containment region such that the vial engagement mechanism and the sled assembly are encapsulated within the safety shield when the safety shield is coupled thereto. The sled assembly, the vial assembly, and the safety shield are configured to inhibit radioactive emissions from within the vial containment region.

Described herein is a medical linear accelerator including an accelerator target structure constructed of a material having a thickness of less than 0.2 radiation lengths, and an accelerator structure to receive an electromagnetic wave and generate an output therapy dose rate of electrons having a beam energy between 4-25 mega-electronvolts (MeV).

A particle beam radiotherapy system has been proposed by using a set of first and second scatterers, whereby a short-duration pulse beam is irradiated to a lesion. When the duration of the radiotherapy beam is 200 milliseconds or less, healthy tissues are selectively protected and only cancer tissues are damaged. For example, it can be used for cancer treatment of brain metastases that may be distributed throughout the entire brain tissues. The positions of the scatterers and the energy of the incident particle beams are optimized according to the position and the volume of the brain tissues.

The present disclosure generally relates to an applicator for radiotherapy and a method for determining a thickness of a scattering foil and modulator therein. According to one embodiment, an applicator for radiotherapy may comprise a housing having a hollow structure with an opening, a scattering foil disposed at an opening of the hollow structure and configured to receive a first radiation and convert a portion of the first radiation into a second radiation while scattering the first radiation, and a modulator disposed inside the hollow structure and configured to modulate an intensity of mixed radiation including the first radiation and the second radiation.

A therapeutic apparatus may be provided. The therapeutic apparatus may include a magnetic resonance imaging (MRI) device configured to acquire MRI data with respect to a region of interest (ROI) and a radiation therapy device configured to apply therapeutic radiation to at least one portion of the ROI. The MRI device may include an annular cryostat having one or more chambers, an annular structure assembly and a recess disposed on the annular structure arrangement. The radiation therapy device may at least include an accelerator and one or more collimation components.

Treatment fields can be produced as part of a treatment plan that achieves a desired balance between field delivery time and dose based on machine parameters and knowledge, such as machine-specific beam production, transport and scanning logic, and/or a maximum treatment time value. The treatment parameters can be adjusted using a graphical user interface so that treatment time or dosimetry is prioritized. As a result, the overall treatment time is reduced, and hence treatment quality and patient experience are improved.

An implantable device has a body that is substantially rigid and has a predetermined shape. The body is further bioabsorbable and has a density less than or equal to about 1.03 g/cc. When the device is implanted in a resected cavity in soft tissue, it causes the cavity to conform to the predetermined shape. The implantable device is further imageable due to its density being less than that of soft tissue such that the boundaries of the tissue corresponding to the predetermined shape can be determined.

There is provided a particle accelerator comprising a waveguide for accelerating electrons along an acceleration path and a magnetron configured to supply a radiofrequency electromagnetic field to the waveguide. An oscilloscope is connected to the magnetron and configured to provide signals indicative of the magnetron output. A processor is configured to receive signals from the oscilloscope and to send data to a central server.

A therapeutic applicator and method may include a wand portion and a module coupled to the wand portion. The module may have a body section and a recess positioned within the body section. The body section may include a prismatic member made of a transparent material and the body section may further include a convex surface. The convex surface may provide a magnification of a view that includes a region surrounding the recess. A radiation source may be positioned within the recess. The body section may have a thickness greater than a diameter of the radiation source which is sufficient to attenuate radiation being emitted from the radiation source while the transparent material of the body section allows visibility of a treatment site that is adjacent to the radiation source. The magnification of the view may fall in range between about 1.1 times to 50.0 times an unmagnified view.

A particle accelerator comprises a waveguide configured to accelerate a beam of electrons along an acceleration path. A diversion channel is configured to convey a beam of electrons along a diversion path. A first magnet arrangement is configured to, at a first location, direct electrons from the acceleration path to the diversion path. A second magnet arrangement is configured to, at a second location, direct electrons from the diversion path to the acceleration path.